Scalper1 News
Small medical-device firm Nevro (NVRO) soared to a new high of 58.87 Monday, eventually closing up 17.6% at 53.33 in more than eight times the average volume. The market seemed to be responding to both its Q1 earnings beat Monday as well as the late-Friday FDA approval of its Senza spinal-cord stimulator for treating chronic pain. Nevro reported Q1 revenue of $9.7 million, up 45% from the year-earlier quarter and about $1.4 million above analysts’ Scalper1 News
Scalper1 News